Using patients' own knowledge of early sensations and symptoms to develop an interactive, individualized e-questionnaire to facilitate early diagnosis of lung cancer.

E-questionnaire Instrument development Internet Lung cancer Questionnaire design Respiratory diseases Tablet computers Think-aloud interviews Usability User-computer interface

Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
13 May 2021
Historique:
received: 20 08 2020
accepted: 28 04 2021
entrez: 14 5 2021
pubmed: 15 5 2021
medline: 21 10 2021
Statut: epublish

Résumé

One reason for the often late diagnosis of lung cancer (LC) may be that potentially-indicative sensations and symptoms are often diffuse, and may not be considered serious or urgent, making their interpretation complicated. However, with only a few exceptions, efforts to use people's own in-depth knowledge about prodromal bodily experiences has been a missing link in efforts to facilitate early LC diagnosis. In this study, we describe and discuss facilitators and challenges in our process of developing and initial testing an interactive, self-completion e-questionnaire based on patient descriptions of experienced prodromal sensations and symptoms, to support early identification of lung cancer (LC). E-questionnaire items were derived from in-depth, detailed explorative interviews with individuals undergoing investigation for suspected LC. The descriptors of sensations/symptoms and the background items obtained were the basis for developing an interactive, individualized instrument, PEX-LC, which was refined for usability through think-aloud and other interviews with patients, members of the public, and clinical staff. Major challenges in the process of developing PEX-LC related to collaboration among many actors, and design/user interface problems including technical issues. Most problems identified through the think-aloud interviews related to design/user interface problems and technical issues rather than content, for example we re-ordered questions to be in line with patients' chronological, rather than retrospective, descriptions of their experiences. PEX-LC was developed into a final e-questionnaire on a touch-screen smart tablet with one background module covering sociodemographic characteristics, 10 interactive, individualized modules covering early sensations and symptoms, and a 12th assessing current symptoms. Close collaboration with patients throughout the process was intrinsic for developing PEX-LC. Similarly, we recognized the extent to which clinicians and technical experts were also important in this process. Similar endeavors should assure all necessary competence is included in the core research team, to facilitate timely progress. Our experiences developing PEX-LC combined with new empirical research suggest that this individualized, interactive e-questionnaire, developed through systematizing patients' own formulations of their prodromal symptom experiences, is both feasible for use and has potential value in the intended group.

Sections du résumé

BACKGROUND BACKGROUND
One reason for the often late diagnosis of lung cancer (LC) may be that potentially-indicative sensations and symptoms are often diffuse, and may not be considered serious or urgent, making their interpretation complicated. However, with only a few exceptions, efforts to use people's own in-depth knowledge about prodromal bodily experiences has been a missing link in efforts to facilitate early LC diagnosis. In this study, we describe and discuss facilitators and challenges in our process of developing and initial testing an interactive, self-completion e-questionnaire based on patient descriptions of experienced prodromal sensations and symptoms, to support early identification of lung cancer (LC).
METHODS METHODS
E-questionnaire items were derived from in-depth, detailed explorative interviews with individuals undergoing investigation for suspected LC. The descriptors of sensations/symptoms and the background items obtained were the basis for developing an interactive, individualized instrument, PEX-LC, which was refined for usability through think-aloud and other interviews with patients, members of the public, and clinical staff.
RESULTS RESULTS
Major challenges in the process of developing PEX-LC related to collaboration among many actors, and design/user interface problems including technical issues. Most problems identified through the think-aloud interviews related to design/user interface problems and technical issues rather than content, for example we re-ordered questions to be in line with patients' chronological, rather than retrospective, descriptions of their experiences. PEX-LC was developed into a final e-questionnaire on a touch-screen smart tablet with one background module covering sociodemographic characteristics, 10 interactive, individualized modules covering early sensations and symptoms, and a 12th assessing current symptoms.
CONCLUSIONS CONCLUSIONS
Close collaboration with patients throughout the process was intrinsic for developing PEX-LC. Similarly, we recognized the extent to which clinicians and technical experts were also important in this process. Similar endeavors should assure all necessary competence is included in the core research team, to facilitate timely progress. Our experiences developing PEX-LC combined with new empirical research suggest that this individualized, interactive e-questionnaire, developed through systematizing patients' own formulations of their prodromal symptom experiences, is both feasible for use and has potential value in the intended group.

Identifiants

pubmed: 33985458
doi: 10.1186/s12885-021-08265-x
pii: 10.1186/s12885-021-08265-x
pmc: PMC8117555
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

544

Subventions

Organisme : Vårdalstiftelsen
ID : 2014-0044
Organisme : Vetenskapsrådet
ID : 2016-01712; 2019-01222
Organisme : Strategic Research Area Health Care Science (SFO-V)
ID : 2-2764/2018 and 2020
Organisme : Cancerföreningen i Stockholm
ID : 191092

Références

Sci Rep. 2019 Nov 11;9(1):16504
pubmed: 31712735
Thorax. 2005 Dec;60(12):1059-65
pubmed: 16227326
J Adv Nurs. 2003 Apr;42(1):57-63
pubmed: 12641812
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Eur J Cancer Care (Engl). 2017 May;26(3):
pubmed: 28497588
BMJ. 2001 May 26;322(7297):1297-300
pubmed: 11375237
Soc Sci Med. 2006 Mar;62(6):1381-91
pubmed: 16168544
NPJ Prim Care Respir Med. 2020 Apr 7;30(1):15
pubmed: 32265450
Stud Health Technol Inform. 2015;210:845-9
pubmed: 25991274
Qual Life Res. 2014 Jun;23(5):1603-7
pubmed: 24307212
Thorax. 2013 May;68(5):451-9
pubmed: 23321602
Chest. 2013 May;143(5 Suppl):e1S-e29S
pubmed: 23649439
Qual Life Res. 2003 May;12(3):229-38
pubmed: 12769135
Thorax. 2005 Apr;60(4):314-9
pubmed: 15790987
Prev Med. 2002 Apr;34(4):436-44
pubmed: 11914050
Br J Cancer. 2015 Mar 31;112 Suppl 1:S6-13
pubmed: 25734397
Br J Gen Pract. 2011 Nov;61(592):e715-23
pubmed: 22054335
Int J Family Med. 2014;2014:187280
pubmed: 25147736

Auteurs

Adrian Levitsky (A)

Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, SE-171 77, Solna, Sweden.
Cancer Proteomics Mass Spectrometry, Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, SE-171 65, Solna, Sweden.

Britt-Marie Bernhardson (BM)

Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, SE-171 77, Solna, Sweden.

Ingela Henoch (I)

Sahlgrenska academy, University of Gothenburg, Institute of Health and Care Sciences, SE-405 30, Gothenburg, Sweden.

Maria Olin (M)

Lung Oncology Center, Theme Cancer, Karolinska University Hospital, SE-171 76, Solna, Sweden.

Karl Kölbeck (K)

Lung Oncology Center, Theme Cancer, Karolinska University Hospital, SE-171 76, Solna, Sweden.

Nadja Rystedt (N)

Center for Medical Technology and Radiation Physics, University Hospital of Umeå, SE-901 85, Umeå, Sweden.

Carol Tishelman (C)

Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, SE-171 77, Solna, Sweden.
Center for Health Economy, Informatics and Health System Research (CHIS), Stockholm Health Care Services (SLSO), Stockholm County Council, SE-113 65, Stockholm, Sweden.

Lars E Eriksson (LE)

Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, SE-171 77, Solna, Sweden. lars.eriksson@ki.se.
School of Health Sciences, City, University of London, Northampton Square, EC1V 0HB, London, UK. lars.eriksson@ki.se.
Medical Unit Infectious Diseases, Karolinska University Hospital, SE-141 86, Huddinge, Sweden. lars.eriksson@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH